PIPERACILLIN ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H27N5O7S
Molecular Weight	517.555
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=CC=CC=C4)C(=O)C1=O

InChI

InChIKey=IVBHGBMCVLDMKU-GXNBUGAJSA-N

InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H27N5O7S
Molecular Weight	517.555
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68010878

Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin sodium salt is used in combination with the β-lactamase inhibitor tazobactam sodium (ZOSYN®) for the treatment of patients with moderate to severe infections caused by susceptible bacteria.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Penicillin-binding protein 1A 45 Target ID: Q8DR59 Gene ID: 934791.0 Gene Symbol: pbpA Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Binding Agent 1076		940.0 nM [IC50]
Penicillin-binding protein 2B 10 Target ID: P0A3M6 Gene ID: 933948.0 Gene Symbol: penA Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Binding Agent 1076		51.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Intra-abdominal infections 50 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8583	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 1993
Skin and skin structure infections 81 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8583	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 1993
Female pelvic infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8583	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 1993
Community-acquired pneumonia 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8583	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 1993
Nosocomial pneumonia 10 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8583	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 1993

C_max

Value	Dose	Co-administered	Analyte	Population
150 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23590897/	4.5 g single, intravenous dose: 4.5 g route of administration: Intravenous experiment type: SINGLE co-administered:		PIPERACILLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
344.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23590897/	4.5 g single, intravenous dose: 4.5 g route of administration: Intravenous experiment type: SINGLE co-administered:		PIPERACILLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23590897/	4.5 g single, intravenous dose: 4.5 g route of administration: Intravenous experiment type: SINGLE co-administered:		PIPERACILLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	Other AEs: Thrombophlebitis, Injection site pain... Other AEs: Thrombophlebitis (4%) Injection site pain (2%) Injection site erythema (2%) Injection site induration (2%) Diarrhea (2%) Loose stools (2%) Rash (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	Other AEs: Thrombophlebitis, Injection site pain... Other AEs: Thrombophlebitis (4%) Injection site pain (2%) Injection site erythema (2%) Injection site induration (2%) Diarrhea (2%) Loose stools (2%) Rash (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf

AEs

AE	Significance	Dose	Population
Rash	1%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Diarrhea	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site erythema	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site induration	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site pain	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Loose stools	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Thrombophlebitis	4%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Rash	1%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Diarrhea	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site erythema	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site induration	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site pain	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Loose stools	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Thrombophlebitis	4%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438 inducer 440

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A5 136 CYP2C8 1057 OAT1 725 OAT3 747	OAT1 395 OAT3 391	CYP3A5 92 P-gp 301

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A4 2633	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A5 201	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A5 201	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/11850258/	no
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	weak [IC50 1140 uM]
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32104494/	yes
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32104494/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT3 391	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/29277663/	yes [Km 172 uM]
OAT1 395	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/29277663/	yes [Km 37 uM]

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-01410	http://www.3bsc.com/index/pro_info.php?id=21622
3B Scientific (Wuhan) Corp	3B2-1697	http://www.3bsc.com/index/pro_info.php?id=56231
abcr GmbH	AB479648	http://www.abcr.com/shop/en/AB479648
Achemtek	0102-022374	http://www.achemtek.com/61477-96-1
AHH Chemical co.,ltd	MT-58012	http://www.ahhchemical.com/product/MT-58012.html
AHH Chemical co.,ltd	MT-58917	http://www.ahhchemical.com/product/MT-58917.html
AK Scientific, Inc. (AKSCI)	J10085	http://www.aksci.com/item_detail.php?cat=J10085
Angene	AGN-PC-0T0LDB	http://www.angenechemical.com/productshow/AGN-PC-0T0LDB.html
Aurora Fine Chemicals LLC	A13.110.313	http://online.aurorafinechemicals.com/info?ID=A13.110.313
Aurum Pharmatech LLC	KM0517	http://www.Aurumpharmatech.com/Product/ProductDetails/KM0517
AvaChem Scientific	4535	http://www.avachem.com/productSearch.asp?4535
BioSynth	W-105153	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/W-105153.html
BLD Pharm	BD239259	http://www.bldpharm.com/products/61477-96-1.html
ChemMol	49424430	http://www.chemmol.com/chemmol/49424430.html
ChemMol	99119834	http://www.chemmol.com/chemmol/99119834.html
Chemspace	CSSB00016990198	https://chem-space.com/CSSB00016990198
Clearsynth	CS-O-14488	https://www.clearsynth.com/en/CSO14488.html
Glentham Life Sciences	GA9881	http://www.glentham.com/products/product/GA9881/
Hairui	HR134010	http://www.hairuichem.com/en/product/61477-96-1.html
iChemical	EBD29493	http://www.ichemical.com/chemicals/cas-61477-96-1
Lab Network	LN00199061	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00199061
LGC Standards	DRE-C16218900	https://www.lgcstandards.com/US/en/p/DRE-C16218900
LGC Standards	LGCFOR0295.00	https://www.lgcstandards.com/US/en/p/LGCFOR0295.00
LGC Standards	MM0295.00	https://www.lgcstandards.com/US/en/p/MM0295.00
Matrix Scientific	97252	https://www.matrixscientific.com/097252.html
MuseChem	R011373	https://www.musechem.com/product/R011373.html
OChem	6047	http://www.ocheminc.com/index.php?act=psearch&pid=477P961
Parchem	44935	https://www.parchem.com/chemical-supplier-distributor/Pipracil-044935.aspx
Smolecule	S589373	https://www.smolecule.com/products/s589373
THE BioTek	bt-505814	https://www.thebiotek.com/product/others/bt-505814
Yuhao Chemical	RT10348	http://www.chemyuhao.com/61477-96-1.html

PubMed

Title	Date	PubMed
Peritonitis in automated peritoneal dialysis: antibiotic therapy and pharmacokinetics.	2001	11887820
Rahnella aquatilis bacteremia in a patient with relapsed acute lymphoblastic leukemia.	2001	11450870
[Achromobacter xylosoxidans bacteremia in a patient with community-acquired pneumonia].	2001	11265630
Infections caused by Flavimonas oryzihabitans.	2001 Apr	11780462
Chronic granulomatous disease: a case report.	2001 Apr	11393130
Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.	2001 Apr-Jun	11432485
An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.	2001 Aug	11589485
[Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp].	2001 Aug	11558128
Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.	2001 Aug	11481298
Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies.	2001 Dec	11810595
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.	2001 Dec	11737119
Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.	2001 Dec 1	11692297
Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).	2001 Feb	11248523
Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock.	2001 Feb	11246321
Study on fluorescent property of degrading products of piperacillin and its analytical application.	2001 Feb	11206555
Increased antibiotic resistance of E. coli exposed to static magnetic fields.	2001 Feb	11180259
Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.	2001 Feb	11165117
Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.	2001 Jan	11252548
[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].	2001 Jan 10	11798851
[Surveillance of bacterial resistance in Shanghai].	2001 Jan 10	11798844
Acinetobacter infections in patients with human immunodeficiency virus infection: microbiological and clinical epidemiology.	2001 Jan-Feb	11125229
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).	2001 Jul	11502382
Pulmonary infiltration with eosinophilia (PIE) syndrome induced by antibiotics, PIPC and TFLX during cancer treatment.	2001 Jul	11377237
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?	2001 Jul-Aug	11399859
[Mycoplasma pneumonia complicated by acute renal failure].	2001 Jun	11530392
Surveillance of bacterial resistance among isolates in Shanghai in 1999.	2001 Jun	11455503
Complicated urinary tract infections in patients with voiding dysfunction.	2001 Jun	11442992
Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin.	2001 Jun	11422785
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.	2001 Jun	11389111
Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit--an infection control study.	2001 Mar	11226649
Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates.	2001 May	11337223
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Hand infections in patients with diabetes mellitus.	2001 Nov	11727802
Stability of piperacillin and ticarcillin in AutoDose infusion system bags.	2001 Nov	11724082
In vitro antimicrobial susceptibility of Aerococcus urinae to 14 antibiotics, and time-kill curves for penicillin, gentamicin and vancomycin.	2001 Nov	11679554
Immediate remission obtained by minocycline in a patient with histiocytic necrotizing lymphadenitis.	2001 Oct	11688834
Nosocomial pneumonia in pediatric patients: practical problems and rational solutions.	2002	11888355
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology.	2002 Feb	11897080
Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999.	2002 Feb	11897073
Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue.	2002 Feb	11892900
Antibiotic-induced recurring interstitial nephritis.	2002 Jan	11793135
Surveillance for antimicrobial resistance in Croatia.	2002 Jan	11749742

Patents

Sample Use Guides

In Vivo Use Guide

The usual total daily dose of ZOSYN® for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). The usual duration of ZOSYN® treatment is from 7 to 10 days. ZOSYN® should be administered by intravenous infusion over 30 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

The MIC values for piperacillin/tazobactam were: 1-4 ug/ml (Escherichia coli ATCC 25922), 0.5-2 ug/ml (Escherichia coli ATCC 35218), 1-8 ug/ml (Pseudomonas aeruginosa ATCC 27853), 0.06-0.5 ug/ml (Haemophilus influenzae ATCC 49247), 0.25-2 ug/ml (Staphylococcus aureus ATCC 29213), 0.12-0.5 ug/ml (Bacteroides fragilis ATCC 25285), 4-16 ug/ml (Bacteroides thetaiotaomicron ATCC 29741).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:33 GMT 2025`
Record UNII	9I628532GX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIPERACILLIN ANHYDROUS

Common Name

English

PERACIN

Preferred Name

English

Piperacillin [WHO-DD]

Common Name

English

PIPERACILLIN [MART.]

Common Name

English

PIPERACILLIN, ANHYDROUS

Common Name

English

PIPERACILLIN [JAN]

Common Name

English

piperacillin [INN]

Common Name

English

PIPERACILLIN [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175497